GMiA calls on Australian government to think before irreversible damage occurs to the generic medicines industry

13 March 2014
drugs_pills_tablets_big

At the Annual Professional Pharmacy (APP) conference in Australia today, Mark Crotty, chairman of the Generic Medicines Industry Association (GMiA), called on government to think before irreversible damage occurs to the generic medicines industry in Australia.

Mr Crotty highlighted that Pharmaceutical Benefits Scheme (PBS) reform is delivering more savings than expected and to avoid inflicting irreversible damage to the generic medicines industry, it is important that there are no more damaging price cuts to generic medicines.

These unforecast and unplanned savings are most damaging to the generic medicines sector and disproportionately damage the generic medicines industry model placing at risk a viable generic medicines industry and patient access to medicines. Policy changes are urgently required, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics